All News

EULAR19.abstract.jpg (keep)

EULAR 2026: Industry Press Releases

Jack Cush, MD

Pharmaceutical companies are presenting pivotal clinical trial results and key data analyses at the EULAR 2026 Congress (June 3–6, London). Below is a summary of their most important studies — many of which are registration-enabling or will directly shape treatment decisions in rheumatic diseases.

Read Article
RheumNow Podcast square

Quiz Talk (5.22.2026)

Jack Cush, MD

Dr. Jack Cush talks of birthdays, Quizzes and journal articles this week on the podcast.

Read Article
H2H.BKZ.RZB

BE BOLD Week 16 data - Bimekizumab vs. Risankizumab in PsA

Jack Cush, MD

UCB has released the Week 16 results from BE BOLD trial that will be presented at EULAR 2026 in London on Saturday, June 6.

Read Article
pediatric eye uveitis

Immune-Mediated Inflammatory Diseases Following Uveitis

Jack Cush, MD

A Korean insurance claims data study showed children and adolescents diagnosed with uveitis have a 7-fold increased risk of developing an immune-mediated inflammatory disorder (IMID).

Read Article
SI AS SpA ACR

Another IL-17A inhibitor (Vunakizumab) for active Ankylosing Spondylitis

Jack Cush, MD

Vunakizumab, a novel anti–interleukin (IL) 17A monoclonal antibody, was studied in patients with active radiographic axial spondyloarthritis [r-axSpA] and found to be effective and

Read Article
RheumNow Podcast square

Prescribing Lessons (4.17.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Read Article
Cancer.risk_.jpg

Malignancies Not Increased with Biologic Therapies

Jack Cush, MD

The risk of malignancy in rheumatoid arthritis (RA) patients receiving biologic agents was evaluated by metanalysis of randomized controlled trials (RCTs) and found no significant increased risk of malignancy compared with other disease-modifying antirheumatic drugs (DMARDs) or with placebo.

Read Article
colon.Crohns.jpg

JAMA Guideline on the Management of Crohn Disease

Jack Cush, MD

JAMA has published a current Clinical Guidelines Synopsis on the Management of Crohn Disease (CD) in Adults.

Read Article
Canada.maple.leaf

Updated CRA/SPARCC Recommendations for Axial Spondyloarthritis

Jack Cush, MD

In 2024, the Canadian Rheumatology Association (CMA) and the Spondyloarthritis Research Consortium of Canada (SPARCC) published a comprehensive set of 56 treatment recommendations for the management of axial spondyloarthritis. This first update is focused on the reassessment of IL-17i recommendations.

Read Article
RheumNow Podcast square

What’s New PsA? (4.3.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and major articles from this week, including FDA safety warnings, reports from AAD, PsA trials.

Read Article
IL-23i vs IL-17i in PsABIOnd (n=1,141): 12mo persistence (~77%), joint/skin response, MDA, and PROs similar across both. GUS matched IL-17i despite treating more biologic-experienced pts (15% vs 8% on 4th-line). GI AEs higher with IL-17i (11% vs 7%). @RheumNow #EULAR2026 POS0045

Jiha Lee JihaRheum ( View Tweet)

What’s new in (WIN) PsA session. A preview of the BE BOLD study: Bimekizumab vs risankizumab on ACR50 in active #PsA 49.1% vs 38.4% (p=0.008). The first head-to-head biologic trial to show joint superiority in PsA. Dual IL-17A/F blockade important. Abstr #LB0001 @RheumNow

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

BE BOLD Week 16 data - Bimekizumab vs. Risankizumab in PsA UCB has released the Week 16 results from BE BOLD trial that will be presented at EULAR 2026 in London on Saturday, June 6. This head-to-head trial demonstrates that at week 16, bimekizumab (BKZ) yielded superior ACR50 https://t.co/VVBaNdWIuQ
Dr. John Cush RheumNow ( View Tweet)
Another IL-17A inhibitor (Vunakizumab) for active Ankylosing Spondylitis Vunakizumab, a novel anti–interleukin (IL) 17A monoclonal antibody, was studied in patients with active radiographic axial spondyloarthritis [r-axSpA] and found to be effective and tolerable. https://t.co/4WMLbcPLOs
Dr. John Cush RheumNow ( View Tweet)
Prospective study of 40 newly Dx, Tx-naïve RA pts starting MTX; Of serum cytokines tested, high baseline IL-6 & IL-17 was assoc w/ nonresponse to MTX. Yet, still not good response biomarkers. TNF-α & GM-CSF did not assoc w/ MTX outcomes https://t.co/YIQKop9LMH https://t.co/XxwcRsKwoM

Links:

Dr. John Cush RheumNow ( View Tweet)
Another IL-17A inhibitor (Vunakizumab) for active Ankylosing Spondylitis Vunakizumab, a novel anti–interleukin (IL) 17A monoclonal antibody, was studied in patients with active radiographic axial spondyloarthritis [r-axSpA] and found to be effective and tolerable. https://t.co/y0mw7tRWbs
Dr. John Cush RheumNow ( View Tweet)
https://t.co/4UQlqwujiR 2026 brought together leading rheumatology experts for two days of practical, clinically focused education. Now you can watch the full program On Demand. Highlights include: • RA mortality trends and the mucosal hypothesis • IL-23 vs IL-17 inhibitor https://t.co/YMfxa7PDXF

Links:

Dr. John Cush RheumNow ( View Tweet)
TRACE study in 90 active axSpA, biologic-naïve, Rx w/ secukinumab 150 mg; @wk16 ASDAS remission in 30 (35%)& 55 incr SEC to 300 mg. By wk 24, 22% of 300 mg achieved ASDAS remission; but without signif change in MRI inflamm (SPARCC). Most MRI changes in 1st 4wks https://t.co/pMMtrxxDLh
Dr. John Cush RheumNow ( View Tweet)
OL phase 2 study 50 active systemic JIA pts Randomized to IL-1 inhibitor, firsekibart or TCZ q2wk x 24 wks. At day 28, modified ACR Pedi 30response (no fever) favored FIRS 3mg dose (94% vs 75% vs 82%). Also higher ACR Pedi 70/90 responses & steriod tapers. https://t.co/8bdCLUFFLT https://t.co/ddQe7k25UE

Links:

Dr. John Cush RheumNow ( View Tweet)
Updated CRA/SPARCC Recommendations for Axial Spondyloarthritis The original CRA/SPARCC recommendations endorsed IL-17i and TNFi as equivalent second-line options for adults with active axSpA who fail an adequate NSAID trial. JAK inhibitors were reserved for patients with prior https://t.co/e1iLSksgYj
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×